Investor Presentaiton
Benefiting from strong demand of herbal supplement & vitamin
products, SIDO continued delivering strong results up to 9M21
(IDR Billion - Unaudited)
9M21
SALES
SIDOMUNCUL
GROSS PROFIT
EBIT
NPAT
2,776
1,562
1,079
865
+23% YoY
+28% YoY
+37% YoY
+35% YoY
9M20
2,257
1,217
786
641
·
Surging demand from domestic market boosted SIDO topline performance in 3Q21 (+41% yoy).
Tolak Angin group and Healthy Drink products were the top growth contributors.
• Overall export sales increased by 39%, contributing 2.6% of total sales as of 9M21. Nigeria and
Malaysia are still top export contributors as of 9M21.
A&P cost ratio was stable at 9% of sales. Overall, OPEX ratio to sales was 18%, lower compared
to historical ratio (20%-21%) due to higher sales performance and efficient operations.
SIDO continued to improve its margin and booked higher NPAT growth of 35% with margin of
31%.
29View entire presentation